- Home
- DAVA vs UNCY Comparison
DAVA vs UNCY Comparison
Compare DAVA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | UNCY |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 150.1M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DAVA | UNCY |
|---|---|---|
| Price | $3.06 | $5.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $13.50 | ★ $25.67 |
| AVG Volume (30 Days) | 167.7K | ★ 680.7K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.07 | $582.86 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $3.72 |
| 52 Week High | $10.20 | $8.74 |
Technical Indicators
Market Signals| Indicator | DAVA | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 47.30 |
| Support Level | $2.64 | $4.81 |
| Resistance Level | $3.22 | $5.86 |
| Average True Range (ATR) | 0.14 | 0.22 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 42.05 | 29.01 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.